Oncology

Chapters

Transcript

Video

Shayna Sarosiek, MD discusses WM-NET 1 trial

Deep responses following treatment with Ioncastuximab tesirine (WM-NET1 trial) in patients with Relapsed/Refractory including those with high risk, TP53-altered Waldenstrom macroglobulinemia.

Related Presenters

Shayna Sarosiek, MD.

Shayna Sarosiek, MD

Medical Oncology

View full profile

ADVERTISEMENT

Related Videos

Reid W. Merryman, MD discusses results of a multicenter phase II trial Video

Reid W. Merryman, MD discusses results of a multicenter phase II trial

Jacqueline Garcia, MD discussed results from the Phase # VERONA study Video

Jacqueline Garcia, MD discussed results from the Phase # VERONA study

Jennifer Brown, MD, PhD discusses results form the ALPINE trial Video

Jennifer Brown, MD, PhD discusses results form the ALPINE trial

Austin Kim, MD discusses phase I/II study Video

Austin Kim, MD discusses phase I/II study

Omar Nadeem, MD discusses results of the Phase II d-PRISM study Video

Omar Nadeem, MD discusses results of the Phase II d-PRISM study

Jorge J. Castillo, MD discusses results from a multicenter phase 2 Study Video

Jorge J. Castillo, MD discusses results from a multicenter phase 2 Study